Unipolar Depression Treatment Guidelines – Detailed Study Notes

DSM Criteria for Unipolar Major Depression

  • Unipolar major depression (major depressive disorder) diagnosed when:
    • There is a history of at least one major depressive episode and no history of mania or hypomania.
    • The episode is not attributable to medications or another medical condition.
    • Symptoms have been present for at least two weeks.
    • At least one of the core symptoms must be depressed mood or anhedonia (loss of interest or pleasure).
    • A total of five or more symptoms from the following list must be present, with either depressed mood or anhedonia as one of them:
    • Insomnia or hypersomnia (sleep disturbance)
    • Changes in appetite or weight (increase or decrease)
    • Psychomotor retardation or agitation
    • Fatigue or low energy
    • Diminished ability to think, concentrate, or make decisions
    • Feelings of worthlessness or excessive or inappropriate guilt
    • Recurrent thoughts of death or suicidal ideation
  • Notes:
    • The presence of depressed mood OR anhedonia is required; both can be present.
    • Depression is a pervasive, disabling condition affecting multiple areas of functioning.
    • Context: Depression is highly prevalent across healthcare settings and can be evident in any patient encounter.

Guiding Principles for Treating Unipolar Depression

  • General principle 1: Know your goals and measure them with a validated tool
    • Goals should be established collaboratively with the patient (shared decision-making).
    • Progress should be measured with a validated outcome tool; use a clearly defined goal for treatment and evaluate progress using the same tool.
    • Common treatment goals include achieving response, remission, or both.
  • Definitions:
    • Response: improvement of
      response≥50%\text{response} \ge 50\%
    • Remission: resolution of the depressive syndrome.
    • Both response and remission are possible; monitor using a clinician-administered depression rating scale or patient-reported measures.
  • Validated outcome tools commonly used in research and practice:
    • Hamilton Depression Rating Scale (HDRS)
    • Montgomery–Åsberg Depression Rating Scale (MADRS)
    • Patient Health Questionnaire-9 (PHQ-9)
  • Note on measurement tools:
    • Use tools not to label patients, but to ensure consistent communication, track progress, and guide treatment decisions.
    • The PHQ-9 is a key example of a validated, widely used tool for monitoring depression in primary and specialty care.

The PHQ-9: Structure, Scoring, and Interpretation

  • The PHQ-9 consists of 9 questions corresponding to the DSM criteria for depressive disorder.
  • Each item is scored by the patient as:
    • 0 = Not at all
    • 1 = Several days
    • 2 = More than half the days
    • 3 = Nearly every day
  • The time window for the PHQ-9 in this context is the past two weeks.
  • Questions cover the following domains (in order as presented in the tool):
    • 1) Little interest or pleasure in doing things (anhedonia)
    • 2) Feeling down, depressed, or hopeless
    • 3) Trouble falling or staying asleep, or sleeping too much
    • 4) Feeling tired or having little energy
    • 5) Poor appetite or overeating
    • 6) Feeling bad about yourself—or that you are a failure or have let yourself or your family down
    • 7) Trouble concentrating on things (e.g., reading the newspaper, watching television)
    • 8) Moving or speaking so slowly that others might notice; or the opposite—being so fidgety/restless that you have been moving around more than usual
    • 9) Thoughts that you would be better off dead or of hurting yourself in some way
  • Scoring total:
    • Total score S is calculated as:
      S=∑<em>i=19x</em>i,xi∈0,1,2,3S = \sum<em>{i=1}^{9} x</em>i, \quad x_i \in {0,1,2,3}
  • Interpretation of PHQ-9 total score (guides treatment decisions and communicates severity consistently):
    • 0 \le S \le 4: None or minimal depression
    • 5 \le S \le 9: Mild depression
    • 10 \le S \le 14: Moderate depression
    • 15 \le S \le 19: Moderately severe depression
    • 20 \le S \le 27: Severe depression
  • Clinical use and clinical judgment:
    • The scoring helps standardize communication and track change over time, but treatment decisions should also consider symptom duration and functional impairment.
    • Avoid labeling or pigeonholing; use the score to inform collaborative decision-making and to evaluate response to treatment.
  • Treatment planning thresholds (informed by PHQ-9 category):
    • 0-4: Likely no treatment needed; monitor and reassess as needed.
    • 5-9: Mild depression; decisions based on duration and impairment; consider watchful waiting, psychotherapy, lifestyle interventions, or pharmacotherapy depending on context.
    • 10-14: Moderate depression; stronger consideration of active treatment (psychotherapy, pharmacotherapy, or both).
    • 15-19: Moderately severe; pharmacotherapy and psychotherapy, or pharmacotherapy alone, typically recommended depending on patient factors.
    • 20-27: Severe; pharmacotherapy is indicated, with psychotherapy as appropriate; ensure safety planning for suicidality.
  • Role of clinical judgment:
    • The clinician must integrate duration of symptoms and functional impairment when selecting the treatment plan.
    • Engage the patient in the decision-making process and ensure safety, especially when suicidality is present.
  • Practical note:
    • The PHQ-9 is commonly available in downloadable guidelines materials and is used to standardize the interpretation of scores across clinicians and settings.

Mini Role-Play Illustration: Using the PHQ-9 in Practice

  • Scenario setup:
    • The clinician introduces themselves and explains the purpose of the PHQ-9, asking questions about the patient’s experience over the past two weeks.
    • A card with response categories is provided to the patient to guide answers (noting the four-category options: Not at all, Several days, More than half the days, Nearly every day).
  • The sequence of questions (as demonstrated in the transcript) includes:
    • 1) Have you had little interest or pleasure in doing things?
    • 2) Have you been feeling down, depressed, or hopeless?
    • 3) Have you had trouble falling asleep or staying asleep, or sleeping too much?
    • 4) Have you been feeling tired or having little energy?
    • 5) Have you had changes in your appetite or weight?
    • 6) Have you been feeling bad about yourself or that you are a failure or let yourself/family down?
    • 7) Have you had trouble concentrating?
    • 8) Have you been moving or speaking so slowly that others could have noticed, or the opposite—being so fidgety/restless you have been moving around more than usual?
    • 9) Have you had thoughts that you would be better off dead or hurting yourself in some way?
  • Communication approach demonstrated:
    • The clinician uses patient-friendly language and normalizes discussing difficult topics.
    • The patient is invited to rate each item using the provided categories and to reflect on the past two weeks.
    • After completing the PHQ-9, the clinician explains how the score will guide treatment planning and emphasizes collaborative goal setting.
  • Safety and follow-up:
    • Acknowledge the sensitivity of suicidality questions and provide support.
    • Use the PHQ-9 score in conjunction with history and functional assessment to plan next steps and follow-up.